10-Q - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Filer)

Thu, May 8, 9:37 PM (14 days ago)

**Shuttle Pharmaceuticals Holdings, Inc. (SHPH) Q1 2025 Financial Summary** **Financial Health and Performance:** - **Revenue:** $0 (no revenue generated). - **Net Loss:** $3.05 million, up 76% from $1.73 million in Q1 2024. - **Operating Expenses:** $2.95 million, a 113% increase from $1.38 million in Q1 2024. - **Research & Development (R&D):** $1.57 million, up 169% from $0.59 million. - **General & Administrative:** $0.597 million, up 84% from $0.325 million. - **Legal & Professional:** $0.78 million, up 65% from $0.474 million. - **Cash Flow:** Negative operating cash flow of $2.53 million, a 104% increase in cash used from $1.24 million in Q1 2024. - **Cash Position:** $4.51 million in cash and cash equivalents, up from $1.92 million in Q1 2024. - **Working Capital:** $3.18 million, up from $0.68 million in Q1 2024. **Key Metrics and Trends:** - **Profit Margins:** Negative, with a net loss margin of 100% due to zero revenue. - **Cash Burn:** High, with significant increases in operating expenses and cash used in operations. - **Liquidity:** Improved, with increased cash position and working capital, but still reliant on external financing. - **Future Operations Impact:** The company's ability to continue as a going concern is dependent on raising additional equity or debt financing. **Uncertainties and Future Outlook:** - **Funding:** The company faces substantial doubt about its ability to continue as a going concern within one year. - **Clinical Trials:** Progressing with Ropidoxuridine clinical trials, but reliant on external CRO and regulatory approvals. - **Listing Compliance:** At risk of delisting from Nasdaq if the stock price does not meet the minimum bid price requirement by June 30, 2025. **Management's Discussion:** - The company is focused on advancing its R&D programs, particularly the Ropidoxuridine clinical trial. - Management is actively seeking additional financing to support ongoing operations and clinical trials. - The company is addressing material weaknesses in its internal controls over financial reporting.